Tiamson, Cris Reyden B.
HRN: 22-48-67 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/08/2023
CEFUROXIME 750MG (VIAL)
05/08/2023
05/14/2023
IV
325mg
Q8h
URTI
Waiting Final Action
Indication: Empiric Type of Infection: URTI Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes